IP Library Granted Patent US 7,951,614
Granted Patent B2
US 7,951,614 · App. 12/549,207 · Granted May 31, 2011

Methods and compositions for the production of monoclonal antibodies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,951,614
App. No.
12/549,207
Granted
May 31, 2011
Kind
B2
Abstract

The present invention comprises compositions and methods for making monoclonal antibodies. The present invention further comprises vectors that replicate the immune system components, particularly an antigen-presenting cell (APC) element of the immune synapse. Additionally, the present invention may further comprise synthetic T-cells.

Claims (15)

1. A composition, comprising a synthetic antigen presenting cell (APC), wherein the synthetic APC comprises a major histocompatibility complex (MHC) protein bound to a first colloidal metal particle, a structural protein bound to a second colloidal metal particle, and a co-stimulatory protein B7 bound to a third colloidal metal particle, wherein the first, second and third colloidal metal particles are bound to each other by scaffolding molecules.

2. The composition of claim 1 , wherein the MHC protein, the structural protein and the co-stimulatory protein B7 are bound indirectly by a binding pair.

3. The composition of claim 2 , wherein the binding pair comprises streptavidin-biotin.

4. The composition of claim 1 , wherein the structural protein is selected from the group consisting of: intracellular adhesion molecule (ICAM), LFA-3, and CD72.

5. The composition of claim 1 , wherein the colloidal metal comprises colloidal gold, colloidal silver, colloidal iron, colloidal aluminum, or colloidal platinum.

6. The composition of claim 1 , further comprising a pharmaceutically-acceptable component comprising excipients, buffers or carriers.

7. The composition of claim 1 , further comprising an adjuvant, wherein the adjuvant comprises liposomes, emulsions, microspheres, biodegradable polymers and polystyrene, alum, heat killed M. butyricum and M. tuberculosis , Pertussis toxin and Tetanus toxin, or LPS and Staphylococcal enterotoxin B.

8. The composition of claim 1 , wherein the MHC protein is an antigen-loaded MHC protein.

9. The composition of claim 1 wherein the colloidal metal particles are the same size.

10. The composition of claim 1 , wherein the colloidal metal particles are different sizes.

11. The composition of claim 10 , wherein the first colloidal metal particle is 32 nanometers (nm), and the second and third colloidal metal particles are 17 nm.

12. The composition of claim 1 , wherein the first, second and third colloidal metal particles are coated with streptavidin and wherein the scaffolding molecule is a biotinylated protein.

13. The composition of claim 12 , wherein the biotinylated protein is human serum albumin (HSA).

14. The composition of claim 1 , wherein the scaffolding molecule is a di-thiol alkane.

15. The composition of claim 1 , wherein the scaffolding molecule is a 2 or 4-arm poly-ethylene glycol (PEG).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2009
From: TAMARKIN, LAWRENCE; PACIOTTI, GIULIO F.
To: CYTIMMUNE SCIENCES, INC.
Reel/Frame 023662/0231 →